Zai Lab Ltd Cash Flow Conversion Efficiency
Zai Lab Ltd cash flow conversion efficiency. Based on the latest financial reports, Zai Lab Ltd (ZLAB) has a cash flow conversion efficiency ratio of -0.104x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-63.41 Million) by net assets ($607.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Zai Lab Ltd (2015–2025)
Cash flow conversion efficiency of Zai Lab Ltd from 2015 to 2025. This chart illustrates how Zai Lab Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Zai Lab Ltd (ZLAB) share price today for real-time trading data and today's change.
Zai Lab Ltd Cash Flow Conversion Ratio Explained
Zai Lab Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Zai Lab Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zai Lab Ltd ranked by their cash flow conversion efficiency. Also see market cap of Zai Lab Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningbo Zhenyu Technology Co. Ltd.
SHE:300953
|
0.016x |
|
Nanjing Tanker Corp
SHG:601975
|
0.041x |
|
Sunway Construction Group Bhd
KLSE:5263
|
0.402x |
|
BSP Financial Group Ltd
AU:BFL
|
0.103x |
|
HMS Networks AB (publ)
ST:HMS
|
0.067x |
|
Zhejiang Publishing & Media Co Ltd
SHG:601921
|
-0.028x |
|
DHT Holdings Inc
NYSE:DHT
|
0.064x |
|
Guizhou Chanhen Chemical Corp
SHE:002895
|
0.028x |
Annual Cash Flow Conversion Efficiency for Zai Lab Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Zai Lab Ltd from 2015 to 2025. Review how much free cash does Zai Lab Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $715.50 Million | $-150.79 Million | -0.211x | +17.52% |
| 2024-12-31 | $840.90 Million | $-214.87 Million | -0.256x | -2.65% |
| 2023-12-31 | $796.12 Million | $-198.18 Million | -0.249x | +29.20% |
| 2022-12-31 | $1.05 Billion | $-367.64 Million | -0.352x | +11.66% |
| 2021-12-31 | $1.38 Billion | $-549.23 Million | -0.398x | -115.41% |
| 2020-12-31 | $1.17 Billion | $-216.06 Million | -0.185x | +71.50% |
| 2019-12-31 | $294.66 Million | $-191.01 Million | -0.648x | -66.87% |
| 2018-12-31 | $251.08 Million | $-97.54 Million | -0.388x | -182.25% |
| 2017-12-31 | $235.17 Million | $-32.37 Million | -0.138x | -122.06% |
| 2016-12-31 | $-51.55 Million | $-32.16 Million | 0.624x | -0.05% |
| 2015-12-31 | $-18.37 Million | $-11.46 Million | 0.624x | -- |
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more